The emerging development of efficient rational discovery strategies and structure-based drug development pipelines is enhancing the efficiency and applicability of molecular glue discovery. Despite the progress in protein science, profound understanding of such compound-mediated protein-protein binding events is broadly insufficient. Detailed knowledge of the interfaces involved, as in the example of IMiDs binding to CRBN, are necessary to design novel molecular glues and develop them into a powerful new medicine.